UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

Journal of thoracic oncology, 2022-04, Vol.17 (4), p.544-557

2022

Volltextzugriff (PDF)

P1.02-014 HER2 Mutations in Chinese Patients with Non-Small Cell Lung Cancer: Topic: Driver Genes in NSCLC, Resistance, and Other

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S494-S495

2017

Volltextzugriff (PDF)

P1.02-014 HER2 Mutations in Chinese Patients with Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S494-S495

2017

Volltextzugriff (PDF)

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

Journal of thoracic oncology, 2019-05, Vol.14 (5), p.867-875

2019

Volltextzugriff (PDF)

Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study

Journal of thoracic oncology, 2021-08, Vol.16 (8), p.1403-1414

2021

Volltextzugriff (PDF)

D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results

Journal of thoracic oncology, 2023-07, Vol.18 (7), p.940-951

2023

Volltextzugriff (PDF)

P2.04-022 Impact of Metastasis Site for Survival of Patients with Advanced Thymic Epithelial Tumors: Topic: Thymic Malignancies Clinical and Translational

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1010-S1010

2017

Volltextzugriff (PDF)

P3.02c-023 Mutation and Prognostic Analyses of PIK3CA in Patients with Completely Resected Lung Adenocarcinoma: Topic: Targeted Therapy

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1285-S1286

2017

Volltextzugriff (PDF)

P3.02a-029 Patients with ROS1 Rearrangement Positive Non-Small Cell Lung Cancer Benefit from Pemetrexed-Based Chemotherapy

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1179-S1180

2017

Volltextzugriff (PDF)

P3.02c-023 Mutation and Prognostic Analyses of PIK3CA in Patients with Completely Resected Lung Adenocarcinoma

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1285-S1286

2017

Volltextzugriff (PDF)

JCES01.11 Altered Expression of Programmed Death-Ligand 1 after Neo-Adjuvant Chemotherapy in Patients with Lung Squamous Cell Carcinoma

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S234-S235

2017

Volltextzugriff (PDF)

JCES01.21 Molecular Profiling and Survival of Primary Pulmonary Neuroendocrine Carcinoma with Completely Resection

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S238-S239

2017

Volltextzugriff (PDF)

P3.02a-024 Response to Crizotinib in a Lung Adenocarcinoma Patient Harbouring EML4-ALK Translocation with Adnexal Metastasis

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1176

2017

Volltextzugriff (PDF)

P1.04-024 Molecular Profiling and Survival of Primary Pulmonary Neuroendocrine Carcinoma with Completely Resection

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S609-S610

2017

Volltextzugriff (PDF)

P1.02-069 Genomic Alterations and Survival in Young Patients under 40 Years with Completely Resected Non-Small Cell Lung Cancer: Topic: Other Mutations in Thoracic Malignancies

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S530-S530

2017

Volltextzugriff (PDF)

P1.02-012 Frequencies of Actionable Mutations and Survival in Variants of Invasive Adenocarcinoma of the Lung

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S493-S494

2017

Volltextzugriff (PDF)

P2.04-022 Impact of Metastasis Site for Survival of Patients with Advanced Thymic Epithelial Tumors

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1010

2017

Volltextzugriff (PDF)

P1.02-069 Genomic Alterations and Survival in Young Patients under 40 Years with Completely Resected Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S530

2017

Volltextzugriff (PDF)

P3.02c-082 Altered Expression of Programmed Death-Ligand 1 after Neo-Adjuvant Chemotherapy in Patients with Lung Squamous Cell Carcinoma

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1327-S1328

2017

Volltextzugriff (PDF)

JCES01.20 Patients with ROS1 Rearrangement Positive Non-Small Cell Lung Cancer Benefit from Pemetrexed-Based Chemotherapy

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S238-S238

2017

Volltextzugriff (PDF)

P3.02a-003 ALK and ROS1 Rearrangements, Coexistence and Treatment in EGFR-Wild Type Lung Adenocarcinoma - A Multicenter Study of 732 Cases

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1160-S1161

2017

Volltextzugriff (PDF)

P1.02-013 Clinicopathological Characteristics and Survival of ALK, ROS1 and RET Arrangements in Non-Adenocarcinoma Non-Small Cell Lung Cancer Patients: Topic: Driver Genes in NSCLC, Resistance, and Other

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S494-S494

2017

Volltextzugriff (PDF)

P1.02-012 Frequencies of Actionable Mutations and Survival in Variants of Invasive Adenocarcinoma of the Lung: Topic: Driver Genes in NSCLC, Resistance, and Other

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S493-S494

2017

Volltextzugriff (PDF)

P1.02-070 Gene Spectrum and Survival Analyses of Pathologic Subtypes in Resected Lung Squamous Cell Carcinoma: Topic: Other Mutations in Thoracic Malignancies

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S530-S531

2017

Volltextzugriff (PDF)

P3.02a-024 Response to Crizotinib in a Lung Adenocarcinoma Patient Harbouring EML4-ALK Translocation with Adnexal Metastasis: Topic: ALK Clinical

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1176-S1176

2017

Volltextzugriff (PDF)

1 – 25 von 53

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Thoracic Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(53)

Sprache

Englisch
(53)

Erscheinungsjahr

n.n

Kollektion

EZB Electronic Journals Library
(53)
Ovid SocietyJournals and Single Titles
(53)
MEDLINE
(6)
IngentaConnect
(2)

Menü

Weitere Dienste

Einstellungen

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

P1.02-014 HER2 Mutations in Chinese Patients with Non-Small Cell Lung Cancer: Topic: Driver Genes in NSCLC, Resistance, and Other

P1.02-014 HER2 Mutations in Chinese Patients with Non-Small Cell Lung Cancer

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study

D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results

P2.04-022 Impact of Metastasis Site for Survival of Patients with Advanced Thymic Epithelial Tumors: Topic: Thymic Malignancies Clinical and Translational

P3.02c-023 Mutation and Prognostic Analyses of PIK3CA in Patients with Completely Resected Lung Adenocarcinoma: Topic: Targeted Therapy

P3.02a-029 Patients with ROS1 Rearrangement Positive Non-Small Cell Lung Cancer Benefit from Pemetrexed-Based Chemotherapy

P3.02c-023 Mutation and Prognostic Analyses of PIK3CA in Patients with Completely Resected Lung Adenocarcinoma

JCES01.11 Altered Expression of Programmed Death-Ligand 1 after Neo-Adjuvant Chemotherapy in Patients with Lung Squamous Cell Carcinoma

JCES01.21 Molecular Profiling and Survival of Primary Pulmonary Neuroendocrine Carcinoma with Completely Resection

P3.02a-024 Response to Crizotinib in a Lung Adenocarcinoma Patient Harbouring EML4-ALK Translocation with Adnexal Metastasis

P1.04-024 Molecular Profiling and Survival of Primary Pulmonary Neuroendocrine Carcinoma with Completely Resection

P1.02-069 Genomic Alterations and Survival in Young Patients under 40 Years with Completely Resected Non-Small Cell Lung Cancer: Topic: Other Mutations in Thoracic Malignancies

P1.02-012 Frequencies of Actionable Mutations and Survival in Variants of Invasive Adenocarcinoma of the Lung

P2.04-022 Impact of Metastasis Site for Survival of Patients with Advanced Thymic Epithelial Tumors

P1.02-069 Genomic Alterations and Survival in Young Patients under 40 Years with Completely Resected Non-Small Cell Lung Cancer

P3.02c-082 Altered Expression of Programmed Death-Ligand 1 after Neo-Adjuvant Chemotherapy in Patients with Lung Squamous Cell Carcinoma

JCES01.20 Patients with ROS1 Rearrangement Positive Non-Small Cell Lung Cancer Benefit from Pemetrexed-Based Chemotherapy

P3.02a-003 ALK and ROS1 Rearrangements, Coexistence and Treatment in EGFR-Wild Type Lung Adenocarcinoma - A Multicenter Study of 732 Cases

P1.02-013 Clinicopathological Characteristics and Survival of ALK, ROS1 and RET Arrangements in Non-Adenocarcinoma Non-Small Cell Lung Cancer Patients: Topic: Driver Genes in NSCLC, Resistance, and Other

P1.02-012 Frequencies of Actionable Mutations and Survival in Variants of Invasive Adenocarcinoma of the Lung: Topic: Driver Genes in NSCLC, Resistance, and Other

P1.02-070 Gene Spectrum and Survival Analyses of Pathologic Subtypes in Resected Lung Squamous Cell Carcinoma: Topic: Other Mutations in Thoracic Malignancies

P3.02a-024 Response to Crizotinib in a Lung Adenocarcinoma Patient Harbouring EML4-ALK Translocation with Adnexal Metastasis: Topic: ALK Clinical

Aktive Filter

Suchergebnisse filtern